Print Page  Close Window
Investor Overview
Company Overview

PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. The company's Sales Services business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. PDI's Product Commercialization Services, including Interpace Diagnostics and the ThyGenX NGS Test, provides full product commercialization and is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. Its Marketing Services division is a pioneer in insight-driven digital c... More >>

Recent News
DateTitle 
02/17/15PDI, Inc. to Hold Fourth Quarter and Full Year 2014 Financial Results Conference Call on Tuesday, March 3, 2015
PARSIPPANY, N.J., Feb. 17, 2015 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that it will release its financial and operating results for the fourth quarter and full year ended December 31, 2014 on Tuesday, March 3, 2015 after the market close.  Management will host a conference call beginning at 4:30 pm Eastern time to discuss the results and answer questions. The dial-in number for the conference call is 877-407-8037 for domestic participants and 201-689-8037 for international... 
Printer Friendly Version
02/04/15PDI, Inc. Subsidiary Interpace Diagnostics Announces PancraGen™ Benefits Reinforced in Pivotal Study Published in Endoscopy
90% Accuracy in Predicting Benign and Malignant Pancreatic Cysts PARSIPPANY, N.J., Feb. 4, 2015 /PRNewswire/ -- PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced today the publication of results of the pivotal PancraGen™ multicenter clinical validation study in the February 2015 issue of Endoscopy.i The study concluded that PancraGen (formerly PathFinderTG®-Pancreas) is 90% accurate at predicting benign and malignant disease in patients with pancre... 
Printer Friendly Version
12/17/14PDI, Inc. Subsidiary Interpace Diagnostics Announces Launch of ThyGenX™ Next-Generation Sequencing (NGS) Test for Cancer Risk Assessment of Thyroid Nodules
Further Enhances Interpace Diagnostics' Thyroid Cancer Test Offering PARSIPPANY, N.J., Dec. 17, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that its molecular diagnostics subsidiary, Interpace Diagnostics, has launched its new next-generation sequencing (NGS) ThyGenX™ test to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules.  Over 525,000 thyroid FNA's (fine needle aspirates) are performed annually and up t... 
Printer Friendly Version
11/03/14PDI Reports 2014 Third Quarter Financial Results; Acquires RedPath Integrated Pathology
Management Will Host Conference Call Today November 3 at 8:00 am ET PARSIPPANY, N.J., Nov. 3, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the fiscal third quarter ended September 30, 2014. Developments during the quarter and recent weeks subsequent to the quarter include: Revenue of $29.2 million for the third quarter of 2014 in line with our expectations Two significant commercialization service contracts with a total value of ap... 
Printer Friendly Version
More >>

Primary IR Contact
Doug Sherk
EVC Group, Inc.
Phone: 415.652.9100
Email: dsherk@evcgroup.com

Stock Quote
PDII (Common Stock)
ExchangeNASDAQ GM (US Dollar)
Price$1.79
Change (%) Stock is Down 0.14 (7.25%)
Volume50,866
Data as of 02/27/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Events and Presentations
Investor Presentation January 2015
Webcasts
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.